Department of Health
Monash University and Atisama Therapeutics will receive MRFF funding to clinically develop a novel inhaled RNA medicine for chronic lung disease.
The new innovation aims to go beyond managing symptoms of lung disease, by slowing functional decline, preventing disease exacerbations and improving long-term outcomes.
A nebuliser device delivers the RNA therapy directly into the lungs-suppressing the inflammation and scarring that drives disease progression.
Read the media release
/Media Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
